After completing his Ph.D at the University of Rouen, in 1994, Dr F. Bost did a post-doc at the Sidney Kimmel Cancer Center in San Diego with Pr Dan Mercola, where he studied the role of the Jun-N terminal Kinase in cancer cell proliferation. Back in France, Dr F. Bost returned to the INSERM laboratory of Dr Y. Le Marchand-Brustel in Nice with a position of Junior researcher at CNRS. He studied the role of MAPK in adipocyte differentiation and the development of type 2 diabetes.
Thanks to their expertise in cancer and diabetes, they discovered the anti-tumoral action of metformin, a drug prescribed for the treatment of type 2 diabetes, in prostate cancer. During the last decade, his team at the Centre Méditerranéen de Médecine Moléculaire (INSERM U1065) in Nice has been working on prostate cancer cell metabolism and more specifically mitochondrial metabolism